Modulation of oral epithelium stem cells by RSpo1 for the prevention and treatment of oral mucositis
Grant Award Details
Grant Type:
Grant Number:
DISC2-13232
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$942,050
Status:
Closed
Progress Reports
Reporting Period:
Year 2 plus NCE
Grant Application Details
Application Title:
Modulation of oral epithelium stem cells by RSpo1 for the prevention and treatment of oral mucositis
Public Abstract:
Research Objective
Locally delivered formulation of RSpo1 protein as an activator of Lgr5+ epithelial stem cells in chemotherapy- or radiation therapy-induced oral mucositis
Impact
Oral mucositis
Major Proposed Activities
Locally delivered formulation of RSpo1 protein as an activator of Lgr5+ epithelial stem cells in chemotherapy- or radiation therapy-induced oral mucositis
Impact
Oral mucositis
Major Proposed Activities
- RSpo1 formulation design and selection for optimal oral delivery
- Activation of Wnt pathway by formulated RSpo1 in-vitro
- Production of RSpo1 protein
- Oral stem cell expansion by RSpo1 to protect and restore chemotherapy and radiation induced oral mucosa damage
Statement of Benefit to California:
The proposed research will provide a new therapy for the prevention and treatment of oral mucositis - a common complication of chemotherapy and radiation therapy for cancer patients in California, the US, and globally. If successful, the product development program will also enable growth of the company which will bring more jobs and opportunities for California citizens, as the company is based here.
